Year: 2014
Type: article
Abstract: Hepatitis E virus (HEV) is one of the main causes of acute hepatitis worldwide. Infections are particularly severe in pregnant women and chronic hepatitis E is known to occur in immunocompromised patients. Current therapy (ribavirin or pegylated alpha interferon) has severe side effects and cannot be employed in all patients. In order to evaluate potential new inhibitors of HEV replication, a virus yield assay can be employed in which the amount of viral RNA progeny released into the culture medium is quantified by reverse-transcription quantitative PCR (RT-qPCR) (Debing et al., 2014).
Source: BIO-PROTOCOL
Authors: Yannick Debing, Kai Dallmeier, Johan Neyts
Institution: KU Leuven
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2526880718